Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
immunotherapy gene therapy |
| gptkbp:administeredBy |
single infusion
specialized treatment centers adults with relapsed or refractory diffuse large B-cell lymphoma patients up to 25 years old with B-cell precursor ALL |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2017 diffuse large B-cell lymphoma B-cell acute lymphoblastic leukemia |
| gptkbp:ATCCode |
L01XL03
|
| gptkbp:blackBoxWarning |
cytokine release syndrome
neurological toxicities |
| gptkbp:brand |
gptkb:Kymriah
|
| gptkbp:cost |
high
|
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:fabricationProcess |
patient-specific cell engineering
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tisagenlecleucel
|
| gptkbp:indication |
relapsed or refractory B-cell malignancies
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
genetically modified autologous T cells targeting CD19
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fever
infections hypotension cytokine release syndrome neurological toxicities |
| gptkbp:storage |
cryopreserved
|
| gptkbp:target |
gptkb:CD19
|
| gptkbp:bfsParent |
gptkb:CAR-T_cell_therapies
|
| gptkbp:bfsLayer |
6
|